Non-syndromic Retinitis Pigmentosa
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Gene Therapy
1100%
Competitive Landscape
1 companies ranked by most advanced pipeline stage
GenSight BiologicsFrance - Paris
1 program1
Gene therapy: GS030-DP AND Medical device: GS030-MDPhase 1/2Gene Therapy1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
GenSight BiologicsGene therapy: GS030-DP AND Medical device: GS030-MD
Clinical Trials (1)
Total enrollment: 10 patients across 1 trials
Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa
Start: Sep 2018Est. completion: Oct 202710 patients
Phase 1/2Active Not Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.